课题基金 / 基金详情

Research for gene therapy of α-glucosidase deficiency using adenoviral vector

Research for gene therapy of α-glucosidase deficiency using adenoviral vector
腺病毒载体治疗α-葡萄糖苷酶缺乏症的基因治疗研究
批准号:
09670687
负责人:
TSUJINO Seiichi
金额:
$2.3万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1997
资助国家:
日本
项目状态:
已结题
起止时间:
1997 至 1999

项目摘要

项目成果

TSUJINO Seiichi的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
α-glucsidase deficiency (acid maltase deficiency: AMD) causes a lysosomal glycogenosis inherited as an autosomal recessive trait. The infantile type of AMD (Pompe disease) leads to early death due to severe dysfunction of cardiac and respiratory muscles and no effective therapy is available. Replication-defective adenovirus vectors offer a promising tool for in vivo gene delivery and gene therapy. We constructed a recombinant adenovirus containing the human α-glucosidase cDNA downstream of the CAG promoter, composed of modified chicken β-actin promoter and CMV-IE enhancer (AxCANAM). We used two animal models to estimate the effects of AxCANAM; naturally generated Japanese quail with AMD and α-glucosidase knockout (AM-KO) mice.First, we used Japanese quail with AMD. When cultured fibroblasts from AMD quails were infected with AxCANAM, α-glucosidase activity in the cells increased in proportion to multiplicity of infection (MOI). When AxCANAM was injected into unilateral superficial pect … More oral muscle of AMD quails, PAS staining showed that glycogenosomes disappeared and stainability of acid phosphatase was reduced in the injected area as compared to the contralateral muscle of the same birds. Biochemically, α-glucosidase activity increased and glycogen content decreased in the injected muscle. Western blot analysis showed that AMD quail muscle injected with AxCANAM expressed human α-glucosidase protein processed to active forms. These results suggest that the human α-glucosidase cDNA transferred by an adenovirus vector was sufficiently expressed, leading to a marked reduction of the glycogen accumulation in the skeletal muscle of AMD quails.Second, we used knockout mice, which was generated with exon 6 of α-glucosidase gene deleted. When AxCANAM was injected into cardiac cavity of AM-KO mice, α-glucosidase activity increased and glycogen content decreased in skeletal muscle, heart, and liver. Stainability of PAS and acid phosphatase was reduced in these tissues. After the injection, α-glucosidase was expressed mainly in liver, but it was thought that the precurcer protein was presumably secreted into blood, uptaked by peripheral tissues, such as muscle, and processed to active α-glucosidase in lysosomes, thereby leading to systemic effects. Less
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
Tsujino,S.,et al.: "Adenovirus-mediated transfer of human acid maltase gene reduces glycogen accumulation in skeletal muscle of Japanese quail with acid maltase deficiency" Human Gene Therapy. 9. 1609-1616 (1998)
Tsujino,S.,et al.:“腺病毒介导的人类酸性麦芽糖酶基因转移减少了酸性麦芽糖酶缺乏的日本鹌鹑骨骼肌中糖原的积累”人类基因疗法。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Tsujino et al.: "Adenovirus-mediated transfer of human acid maltase gene reduces glycogen accumulation in skeletal muscle of Japanese quail with acid maltase deficiency."Hum Gen Therapy. 9. 1609-1616 (1998)
Tsujino 等人:“腺病毒介导的人类酸性麦芽糖酶基因转移减少了酸性麦芽糖酶缺乏的日本鹌鹑骨骼肌中糖原的积累。”Hum Gen 疗法。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Tsujino, S., et al.: "Adenovirus-mediated trnasfer of human acid maltase gene rednces glycogen aconmulation in skefetal muslle of Japanese guail with acid maltase deficieng"Human Gene Therapy. 9. 1609-1616 (1998)
Tsujino,S.,等人:“腺病毒介导的人酸性麦芽糖酶基因转移减少了患有酸性麦芽糖酶缺陷的日本番石榴骨骼肌中的糖原聚集”人类基因疗法。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
辻野精一: "筋糖原病(遺伝性糖代謝異常性ミオパチー)"神経研究の進歩. (印刷中). (2000)
Seiichi Tsujino:“肌糖原病(遗传性葡萄糖代谢障碍性肌病)”神经学研究进展(2000 年出版)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Gene analysis of patients with HHH syndrome and application of the readthrough effect on nonsense mutations of antibiotics for therapy
  • 批准号:
    12670638
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 资助金额:
    $2.05万
  • 财政年份:
    2000
  • 负责人:
    TSUJINO Seiichi
  • 依托单位:
海外基金